arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

ANAVEX LIFE SCIENCES CORP.

AVXL
$1.10 ▼ -0.16 (-12.70%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
85 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

ANAVEX LIFE SCIENCES CORP. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $102.0B
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 4.7% ↗
FCF / Share $-0.00 ↗
Trailing P/E 13.8x
Price / Book 0.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

85-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$7.82M
↑ +246.6% —
FCF / Share Free cash flow per share
$-0.00
↑ +99.8% —
Long-Term Debt Long-term obligations
$345.00
↑ +2.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
17
Cash Quality ↑
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 22 years · 85 quarters